Tonix Pharmaceuticals TNX-102 SL Fibromyalgia 2024

Tonix Pharmaceuticals presented its clinical-stage fibromyalgia treatment TNX-102 SL, highlighting two positive Phase 3 trials with NDA filing expected in H2 2024 and FDA approval anticipated in H2 2025. The company is a CNS-focused biopharma with marketed migraine therapies and a pipeline including a biologic cocaine antidote with FDA Breakthrough Therapy Designation.